SAMHD1 and B-cell chronic lymphocytic leukemia: Since SAMHD1 protected cells against treatment with forodesine and dG (Figure 4), we hypothesized that CLL B cells with SAMHD1 mutations would be particularly susceptible to this combination treatment.